CTOs on the Move

Axon Communications

www.axon-com.com

 
At AXON, we simplify complex information to improve outcomes in healthcare, bringing together the right people with the right expertise to provide our clients with integrated, multichannel communications solutions. As an agency, we are passionate about healthcare communications and combine a personal touch with professionalism.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.axon-com.com
  • 800 Westchester Avenue Suite S-540
    Rye Brook, NY USA 10573
  • Phone: 914.701.0100

Executives

Name Title Contact Details

Similar Companies

WindMIL Therapeutics

WindMIL Therapeutics is a clinical stage oncology cell therapy company. We are leveraging our proprietary platform to develop a novel class of cell therapies called MILs™ (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.

Meso Scale Discovery

Meso Scale Discovery is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Krystal Biotech

At Krystal Biotech, Inc., our mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. We work to accomplish this goal through scientific innovation and operational excellence, believing that `nature operates in the shortest way possible`.

Ventria BioScience

Ventria BioScience is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Myriad

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.